United Therapeutics Corporation Deferred Income Tax Expense (Benefit)
United Therapeutics Corporation (UTHR) reported Deferred Income Tax Expense (Benefit) of $51.60 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-08-05
- United Therapeutics Corporation deferred income tax expense (benefit) for the quarter ending 2026-06-30 was $25.70M.
- United Therapeutics Corporation deferred income tax expense (benefit) for the quarter ending 2026-03-31 was $25.90M.
- United Therapeutics Corporation deferred income tax expense (benefit) for the quarter ending 2025-06-30 was $0.00.
- United Therapeutics Corporation deferred income tax expense (benefit) for the quarter ending 2025-03-31 was $0.00.
- United Therapeutics Corporation deferred income tax expense (benefit) for fiscal 2025 was $97.70M.
- United Therapeutics Corporation deferred income tax expense (benefit) for fiscal 2024 was -$64.10M.
- United Therapeutics Corporation deferred income tax expense (benefit) for fiscal 2023 was -$64.40M.
- United Therapeutics Corporation deferred income tax expense (benefit) for fiscal 2022 was -$50.80M.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month | Deferred Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $25.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $51.60M 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | $25.90M 10-Q · filed 2026-05-06 | ||||
| 2025-12-31 | $97.70M 10-K · filed 2026-02-25 | ||||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | ||||
| 2024-12-31 | -$64.10M 10-K · filed 2026-02-25 | ||||
| 2023-12-31 | -$64.40M 10-K · filed 2026-02-25 | ||||
| 2022-12-31 | -$50.80M 10-K · filed 2025-02-26 | ||||
| 2021-12-31 | -$18.80M 10-K · filed 2024-02-21 | ||||
| 2020-12-31 | -$10.50M 10-K · filed 2023-02-22 | ||||
| 2019-12-31 | -$133.00M 10-K · filed 2022-02-24 | ||||
| 2018-12-31 | $15.70M 10-K · filed 2021-02-24 | ||||
| 2017-12-31 | $66.40M 10-K · filed 2020-02-26 | ||||
| 2016-12-31 | $10.50M 10-K · filed 2019-02-27 | ||||
| 2015-12-31 | $4.60M 10-K · filed 2018-02-21 | $4.63M 10-K · filed 2016-02-25 | |||
| 2014-12-31 | -$2.70M 10-K · filed 2017-02-22 | -$2.71M 10-K · filed 2015-02-24 | |||
| 2013-12-31 | -$47.83M 10-K · filed 2016-02-25 | ||||
| 2012-12-31 | -$57.51M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | -$27.12M derived: sum of 2 quarters · filed 2015-02-24 | $3.85M derived: sum of 3 quarters · filed 2015-02-24 | $37.03M 10-K · filed 2015-02-24 | |
| 2012-09-30 | $30.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | $61.36M derived: sum of 2 quarters · filed 2012-11-01 | $94.53M 10-Q · filed 2012-11-01 | $38.59M derived: sum of 4 quarters · filed 2014-02-25 | |
| 2012-06-30 | $30.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-26 | $64.15M 10-Q · filed 2012-07-26 | $8.21M derived: sum of 3 quarters · filed 2014-02-25 | $27.43M derived: sum of 4 quarters · filed 2014-02-25 | |
| 2012-03-31 | $33.18M 10-Q · filed 2012-04-26 | -$22.77M derived: sum of 2 quarters · filed 2014-02-25 | -$3.54M derived: sum of 3 quarters · filed 2014-02-25 | $32.18M derived: sum of 4 quarters · filed 2014-02-25 | |
| 2011-12-31 | -$55.94M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | -$36.72M derived: sum of 2 quarters · filed 2014-02-25 | -$995.00K derived: sum of 3 quarters · filed 2014-02-25 | $9.44M 10-K · filed 2014-02-25 | |
| 2011-09-30 | $19.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | $54.95M derived: sum of 2 quarters · filed 2012-11-01 | $65.38M 10-Q · filed 2012-11-01 | $17.40M derived: sum of 4 quarters · filed 2013-02-26 | |
| 2011-06-30 | $35.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-26 | $46.16M 10-Q · filed 2012-07-26 | -$1.82M derived: sum of 3 quarters · filed 2013-02-26 | $16.17M derived: sum of 4 quarters · filed 2013-02-26 | |
| 2011-03-31 | $10.44M 10-Q · filed 2012-04-26 | -$37.55M derived: sum of 2 quarters · filed 2013-02-26 | -$19.55M derived: sum of 3 quarters · filed 2013-02-26 | -$338.00K derived: sum of 4 quarters · filed 2013-02-26 | |
| 2010-12-31 | -$47.98M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | -$29.99M derived: sum of 2 quarters · filed 2013-02-26 | -$10.77M derived: sum of 3 quarters · filed 2013-02-26 | -$1.02M 10-K · filed 2013-02-26 | $41.92M 10-K · filed 2011-02-24 |
| 2010-09-30 | $18.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $37.21M derived: sum of 2 quarters · filed 2011-10-27 | $46.96M 10-Q · filed 2011-10-27 | $19.52M derived: sum of 4 quarters · filed 2012-02-28 | |
| 2010-06-30 | $19.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-28 | $28.96M 10-Q · filed 2011-07-28 | $1.52M derived: sum of 3 quarters · filed 2012-02-28 | -$1.37M derived: sum of 4 quarters · filed 2012-02-28 | |
| 2010-03-31 | $9.75M 10-Q · filed 2011-04-28 | -$17.69M derived: sum of 2 quarters · filed 2012-02-28 | -$20.58M derived: sum of 3 quarters · filed 2012-02-28 | ||
| 2009-12-31 | -$27.45M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28 | -$30.34M derived: sum of 2 quarters · filed 2012-02-28 | -$26.74M 10-K · filed 2012-02-28 | -$1.04M 10-K · filed 2011-02-24 | |
| 2009-09-30 | -$2.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | $708.00K 10-Q · filed 2010-10-28 | |||
| 2009-06-30 | $3.60M 10-Q · filed 2010-07-28 | ||||
| 2008-12-31 | -$34.39M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |